PPT Slide
Nuvelo Has a Rapidly Emerging Product Portfolio
Antibody Target Program
- In-house program to develop therapeutic antibodies for cancer and immune-related diseases
- Screening our proprietary gene collection to identify antibody targets
- 4 pre-clinical candidates in monoclonal antibody development
- 13 cell surface targets currently under evaluation
- Potential partnership opportunities